Novo Nordisk A/S (NYSE: NVO)

Novo Nordisk A/S (NYSE: NVO) is a global healthcare company focused on diabetes management. It also develops, manufactures, and markets a broad range of pharmaceutical products. The business is organized into two segments: Diabetes & Obesity Care and Biopharmaceuticals. The Diabetes & Obesity Care segment includes insulin, GLP-1 therapies, oral anti-diabetic medicines, glucagon, protein-based delivery systems, and needles.

As per our previous Kalkine’s Dailies Report published on ‘NVO’ on Jul 29, 2025, Kalkine provided an ‘Buy’ stance on the stock at USD 54.16 based on fundamental analysis and the stock price has now moved up by ~ 13.37% since then and has breached resistance level 2.

Noted below are the details of support and resistance levels provided in our previous report:

Share Price Chart  

Conclusion

Considering the current trading levels, risks associated, and volatile market conditions, notional gains and price action stance, a "Sell" recommendation on ‘NVO’ has been given at the closing market price of USD 61.40 as on 19 September 2025.

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is 19 September 2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level which the stock is expected to reach as per the relative valuation method and/or technical analysis taking into consideration both short-term and long-term scenario.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the London Stock Exchange (LSE) and or REFINITIV. Typically, both sources (LSE and or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.’

Note 6: Dividend Yield may vary as per the stock price movement.